Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Research & Development (2016 - 2025)

Iradimed (IRMD) has disclosed Research & Development for 13 consecutive years, with $674362.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 5.46% to $674362.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 5.7% decrease, with the full-year FY2024 number at $2.8 million, down 0.95% from a year prior.
  • Research & Development was $674362.0 for Q3 2025 at Iradimed, down from $877362.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.0 million in Q1 2023 to a low of -$1.2 million in Q2 2023.
  • A 5-year average of $634175.7 and a median of $604744.0 in 2022 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 477.92% in 2023; the steepest drop was 287.79% in 2023.
  • Iradimed's Research & Development stood at $494851.0 in 2021, then increased by 22.21% to $604744.0 in 2022, then grew by 7.56% to $650435.0 in 2023, then decreased by 12.37% to $569993.0 in 2024, then grew by 18.31% to $674362.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Research & Development are $674362.0 (Q3 2025), $877362.0 (Q2 2025), and $624245.0 (Q1 2025).